CenterBook Partners’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$819K Buy
81,607
+1,432
+2% +$13.2K 0.04% 500
2026
Q2
$671K Sell
80,175
-9,292
-10% -$84.7K 0.03% 454
2026
Q1
$806K Buy
+89,467
New +$1.41M 0.04% 390
2025
Q3
– Sell
-87,721
Closed -$1.6M – 548
2025
Q2
$1.6M Buy
+87,721
New +$1.79M 0.09% 258
2022
Q4
– Sell
-23,779
Closed -$58K – 372
2022
Q3
$58K Buy
+23,779
New +$57K 0.01% 386

Other funds holding ADMA

CenterBook Partners's ADMA Position: Q3 2026 in Review

CenterBook Partners increased its ADMA Biologics (ADMA) stake by 1.8% in Q3 2026, buying an estimated $13.2K and bringing the position to 81,607 shares worth $819K. The position accounts for 0.04% of the portfolio, ranked #500.

CenterBook Partners first reported a position in ADMA in Q3 2022 and has held it in 5 quarters since. The position peaked at $1.6M in Q2 2025. 329 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • CenterBook Partners held 81,607 shares of ADMA Biologics worth $819K as of Q3 2026.
  • CenterBook Partners bought 1,432 ADMA Biologics shares in Q3 2026, an estimated $13.2K.
  • ADMA Biologics made up 0.04% of CenterBook Partners's portfolio in Q3 2026, its #500 holding.
  • CenterBook Partners first reported a position in ADMA Biologics in Q3 2022 and has held it in 5 quarters since.
  • CenterBook Partners's ADMA Biologics position peaked at $1.6M in Q2 2025.
  • 329 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.